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In humoral innate immune response, the complement system is a central player. It attacks 
immediately microbes and foreign particles invading the human body. It is constantly active 
in plasma and can easily be activated on self surfaces and thereby trigger local inflammation 
if efficient regulators are missing. Complement factor H (CFH) is one of the main 
complement regulators in plasma and it has been recently shown to interact with 
apolipoprotein E, a multifunctional protein mostly associated with lipid metabolism thereby 
reducing complement activation in plasma.  
 
This Bachelor thesis project was initiated to learn more about the mechanism of binding 
between Complement factor H (CFH) and apolipoprotein E (apoE). The experiments were 
performed at Helsinki University, Research Programs Unit, Department of Bacteriology and 
Immunology. The laboratory work was done as a part of Jokiranta group’s research. 
 
The aim of this study was to express a recombinant fragment of CFH domains 5-7, obtain 
high-expressing CFH 5-7 Pichia Pastoris clone and isolate apoE from human very low 
density lipoprotein (VLDL) and intermediate density lipoprotein (IDL) particles. These 
isolated molecules will be used in a study investigating the role of CFH and apoE in reducing 
complement mediated inflammation at early stages of atherosclerosis development. 
 
In this thesis the cloning, production and purification of CFH fragment containing three 
domains (CFH 5-7) and apoE isolation from human VLDL and IDL particles are described. 
The CFH 5-7 expression process was performed successfully with a maximum protein purity 
expression. The total amount of the expressed CFH 5-7 (~400 µg) was sufficient to perform 
further experiments. Further optimization of the plasmid transformation procedure will be 
needed to obtain high-expressing CFH 5-7 Pichia Pastoris clone in the future.  
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Komplementtisysteemi on humoraalisen synnynnäisen immuunivasteen keskeinen toimija. 
Se hyökkää välittömästi niitä mikrobeja ja vieraita aineita vastaan, jotka tunkeutuvat 
elimistöön. Se toimii plasmassa jatkuvasti, ja sitä voidaan aktivoida helposti itsepinnoilla ja 
siten se laukaisee paikallisen tulehduksen, jos tehokkaat säätävyysmekanismit puuttuvat. 
Komplementtifaktori H (CFH) on yksi tärkeimmistä komplementtisäätelytekijöistä 
plasmassa, ja sen on viime aikoina osoitettu olevan vuorovaikutuksessa apolipoproteiini E:n 
kanssa, joka on useimmiten lipidien metaboliaan liittyvä multifunktionaalinen proteiini, 
prosessissa, joka vähentää komplementin aktivoitumista plasmassa. 
 
Tämä tutkimus aloitettiin, koska haluttiin tutkia sitoutumismekanismia komplementtifaktori 
H:n (CFH) ja apolipoproteiini E:n (apoE) välillä. Tutkimuksia suoritettiin Helsingin yliopiston 
Bakteriologian ja Immunologian tutkimusohjelmayksikössä. Laboratoriotyö tehtiin Jokiranta-
ryhmän tutkimuksen osana. 
 
Opinnäytetyön tavoitteena oli ilmentää komplementtifaktori H:n 5–7 domeenia, saada CFH 
5–7:n korkeailmentävä Pichia pastoris -klooni ja eristää apoE:ta ihmisen hyvin alhaisen 
tiheyden lipoproteiinin (VLDL) ja välituotetta lipoproteiinin (IDL) partikkeleista. Näitä 
eristettyjä molekyylejä käytetään tutkimuksessa, jossa selvitetään CFH:n ja apoE:n roolia 
ateroskleroosin alkuvaiheessa komplementtivälitteisen tulehduksen vähentämisessä. 
 
Tässä työssä on kuvattu CFH:n 3-domeenin fragmentin (CFH 5–7) kloonaus, tuotanto ja 
puhdistus ja apoE:n eristäminen ihmisen VLDL- ja IDL-partikkeleista. CFH 5–7:n 
ilmentymisen menetelmä suoritettiin onnistuneesti. Tätä varten maksimimäärä puhtainta 
proteiinia ilmennettiin. CFH 5–7:n kokonaismäärä (~400 µg) oli riittävä lisäkokeille. Lisää 
plasmidimuunnosmenettelyn optimointia tarvitaan, jotta saataisiin korkeaa määrää 
ilmentävä CFH 5-7 Pichia Pastoris -klooni tulevaisuudessa. 
Avainsanat Komplementtifaktori H, apolipoproteiini E, ilmentäminen, 
komplementtijärjestelmä 
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 Introduction 
 
The immune system is complex, sensitive, and organized system that helps all living 
beings to manage foreign material penetrating our body. Immunity can be classified into 
two subsystems called acquired and innate immunity. The main differences between 
them is that acquired immune response requires time to recognize the antigen and to 
produce specific antibodies, whereas innate immune response can be activated rapidly 
without antigen recognition and antibody production. The term ‘complement system’ was 
introduced by Paul Ehrlich in 1899 but was first described 10 years earlier by Hans 
Bucher while demonstrating the ability of heat labile substance to kill bacteria in blood 
serum without use of antibodies, hence complementing use of antibodies. The 
evolutionary origin of antibody-independent complement activation (alternative pathway, 
AP), is much more ancient than that of classical antibody-dependent system (classical 
pathway, CP). In addition to the AP the third complement activation system, lectin 
pathway (LP), also seems to have an ancient origin [1; 13; 14.] 
 
The overall goal of this work was to express and purify enough apolipoprotein E (apoE) 
and complement factor H (CFH) proteins for determination of binding mechanism of 
these proteins, using X-ray crystallography. The successful determination of connection 
between CFH and apoE proteins might lead to a breakthrough in treatment or hindering 
the development of Alzheimer`s disease (AD), atherosclerosis and age related macular 
degeneration (AMD). 
 
This final work was done under the supervision of Dr Karita Haapasalo-Tuomainen, 
Ph.D, researcher at Jokiranta group, Haartman institute, Department of Bacteriology and 
Immunology. The Jokiranta group is primarily interested in alternative pathway of 
complement (AP), specifically, in the mechanism, which allows destruction of invading 
microbes while leaving host organism intact. The overall goal of the project is to establish 
how the regulator of alternative complement pathway, CFH, interacts with apoE via 
domains 5-7, ‘marking’ lipids, connected with apoE protein, to not be destroyed during 
AP.  
 
 
2 
 
 
 Theoretical Background 
 
 Function of Complement System 
 
The main goal of complement system is to recognize targets and get activated through 
organized interactions between complement proteins that advance or stop the activation 
process. The importance of the complement system can be illustrated through 
deficiencies of complement components in humans that are associated with diseases 
such as age related macular degeneration (AMD) and atypical hemolytic uremic 
syndrome (aHUS) [1; 15.] 
 
The most obvious purpose of the complement system is to defend against infections. 
The complement system attacks invading microbes directly causing immediate partial 
destruction of the targets and generate target-bound opsonization of C3b molecules, 
thus enhancing phagocytosis. Also, complement system generates substances that 
enhance cellular migration, or chemotaxis, and inflammatory response by releasing C3a 
and C5a anaphylatoxins, thus enabling innate immune response [1.] 
 
Another important role of complement system lies in removal of immune complexes and 
cellular debris from the body. Complement system attacks wreckage and immune 
complexes following their capture by erythrocytes and transportation to be destroyed in 
liver or spleen. Necrotic and apoptotic cells are also cleared by complement system [1; 
16.] 
 
Some complement receptors recognize certain cleavage products of the complement 
activation pathways, thus becoming expressed on lymphocytes. This plays an important 
role in linking adaptive and innate immunity [1.] 
 
 Recognition 
 
The complement system has three specific recognition strategies to separate self from 
non-self structures:  
 
Complement system recognizes non-self targets directly. Usually, innate immunity can 
identify certain patterns appearing on micro-organisms, so called pathogen associated 
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molecular patterns (PAMPs). Such process is mediated by complement components as 
C1q, mannan-binding lectin (MBL) and ficolin [1; 17.] 
 
Also, a plasma protein complement factor H (CFH) that acts as a complement regulator 
of AP, plays an important role in distinguishing self from non-self cells. Partially, CFH 
recognizes self cells by binding to surface deposited C3b and self surface sialic acids 
and glycosaminoglycans [1; 18.] 
 
To prevent complement attack, host cells express membrane-bound complement 
regulatory proteins. On apoptotic and necrotic cells these surface regulators are missing 
and are therefore attacked by complement. It has been proposed that phagocytosis of 
apoptotic and necrotic cells requires two signals. Complement component C1q receives 
signals from nucleic acids exposed by apoptotic cells, whereas loss of surface 
complement regulators acts as missing self signals. This process promotes complement 
activation and opsonization of the target leading to destruction of the cell [1; 19.] 
 
 Activation  
 
After differentiating self from non-self targets using described three recognition 
mechanisms the complement becomes activated. The activation may progress through 
three pathways: classical pathway (CP), alternative pathway (AP) and lectin pathway 
(LP). Upon activation, all three pathways end the same way: with the generation of the 
active enzyme, C5-convertase, initiating activation of the terminal pathway (TP) and 
formation of the membrane attack complex (MAC) [1.] 
 
 Alternative Pathway (AP) 
 
AP along with other two possible complement pathways is highly dependent on 
component C3 since all major processes are possible only through activation of this 
molecule. C3 is a 185 kDa plasma protein composed of two chains, called α and β 
chains. Activation of AP is spontaneous and is initiated via formation of metastable 
C3(H2O) by the process of low rate hydrolysis of C3 in human plasma. Following its 
formation, C3(H2O) can bind factor B within milliseconds thus leaving it exposed to 
cleavage by factor D following formation of C3(H2O)Bb complex, also known as C3-
convertase. Fluid phase C3 is then cleaved by this complex into two fragments: C3a and 
C3b. Freshly formed C3b can then attach onto any available biological surfaces within a 
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short time, whereas smaller fragment C3a (9 kDa) is released and serves as an 
anaphylatoxin and chemotactic factor [1; 20; 21.] 
 
Complement factor D (CFD) is a 26 kDa serine protease. During AP factor D cleaves 
single chain factor B only when it is connected to C3(H2O) or C3b. This cleavage is 
possible due to conformational change in factor B during the C3(H2O)(C3b) complex 
formation, which leaves factor B exposed to activation by factor D. When cleaved, factor 
B is divided into fragments Ba (30 kDa), which is released into liquid phase, and Bb (60 
kDa), which serves as serine protease in newly formed C3bBb complex [1; 22.] 
 
The cleaved C3b can covalently bind to any target surface due to exposed thioester 
group. The continuation of AP may occur on any target’s surface where C3b is bound to. 
At this point C3b can interact with factor B or CFH, starting molecular process of self/non-
self differentiation of AP. After the formation of C3-convertase properdin, or factor P, 
which is the only positive regulator of complement activation can further stabilize the 
C3bBb complex, leading to the formation of C3bBbP. Development of AP is achieved at 
this stage by cleavage of fluid phase C3 to produce enough C3b, which enables forceful 
opsonization of the target. C3bBbP is a stable compound, which may bound to an 
additional C3b causing formation of surface bound C5-convertase C3bBbC3b that 
cleaves fluid phase C5 to C5b, thus activating the TP [1; 23.] (Figure 1) 
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Figure 1: Alternative complement pathway. C3(H2O) binds factor B and gets exposed to cleavage 
by factor D following formation of C3(H2O)Bb complex, C3-convertase, which is then 
cleaved into C3a and C3b particles. C3b then gets attached onto the cell membrane. 
C3b is then further stabilized by properdin and factor B, leading to the formation of 
C3bBbP, which can further react with C3b resulting in the formation of surface-bound 
C5-convertase. 
 
 Terminal Pathway (TP) 
 
C5 is structurally related to C3 molecule, consisting of α (~140 kDa) and β (~80 kDa) 
chains, linked together with disulfide bonds. C5 does not have exposed thioester group 
during conversion of C5 to C5a and C5b, so it cannot covalently bind to target surfaces. 
Because of that, C5 covalently binds to C3bBbC3b complex and becomes exposed for 
cleavage by Bb. After cleavage, C5 releases a powerful anaphylatoxin, C5a, in the fluid 
phase while the C5b fragment remains attached to C3b in the complex. Following C5b 
binding, two single chain proteins C6 (~104 kDa) and C7 (~92 kDa) bind to C5b in 
sequence. The attachment of C7 to C6 leads to a conformational change in the C5b67 
complex, resulting in its release from the C5-convertase to fluid phase. Following the 
release, the majority of C5b67 complexes become inactivated by S-protein or by C8. 
However, small number of complexes can reach the membrane and connect tightly to 
the target membrane [1; 24.] 
 
Component C8 is a molecule that has similarities with C6 and C7 and is comprised of α 
(64 kDa), β (64 kDa) and γ (22 kDa) chains. The C8 α subunit is the first complement 
protein that penetrates the cell membrane. C8 has a two-fold role: it inhibits attachment 
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of C5b67 in the fluid phase to the membrane and promotes MAC formation when 
complex is attached to the surface. When C8 is attaching to the surface-attached C5b67 
complex, it deepens the attachment to the membrane and enables binding of the last 
complement component C9 to C8. C9 is a single chain protein (69 kDa) like C6, C7 and 
C8. While attached to the complex through C8, C9 becomes unfolded and serves as a 
binding site for up to 12-16 additional C9 components that together form a 
transmembrane pore [1; 25.] 
 
 Regulation 
 
In the AP activation cascade C3b must attach to the target’s surface within a short period 
of time to avoid degradation in fluid phase. Also, formed C3-convertases are vulnerable 
to degradation in the absence of properdin. However, complement activation requires 
more efficient means of control because of the explosive propagation due to efficient 
amplification steps of the system. Without specific regulation activation of AP can 
become harmful even for the host and consume components needed for activation of 
AP, leading to acquired complement deficiency and complement inactivity [1.] 
 
The specific regulators for AP include complement receptor 1 (CR1), decay accelerating 
factor (DAF) and CFH, factor H-like protein 1 (CFHL-1), carboxypeptidase N (CPN), 
factor I (CFI), properdin (factor P), clusterin, S-protein (vitronectin), membrane cofactor 
protein (MCP), complement receptor of the Immunoglobulin family (CRIg) and CD59 
(protectin). CFH, CFHL-1, CPN, properdin, clusterin and S-protein are fluid phase 
regulators, while CR1, DAF, MCP, CRIg and CD59 are membrane-associated 
regulators. Most of those specific regulators consist of four or more short-consensus 
repeat (SCR) domains arranged in row. Each SCR is a round domain generally 
consisting of ~ 60 amino acids [1.] 
 
 Complement Factor H (CFH) 
 
The activation of AP seems to be linked to comparatively great amount of polyanions on 
the cell surface, including glycosaminoglycans or sialic acids. These structures prefer 
binding to CFH rather than factor B. CFH is a cofactor that is required for the inactivation 
of C3b by factor I. CFH also contributes to reduced production C3-convertases as it 
inhibits binding of factor B to C3b. Furthermore, binding of CFH on C3 convertase 
accelerates the decay of AP convertases [1; 26.] (Figure 2) 
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Figure 2: Alternative pathway regulation by complement factor H. CFH acts as a cofactor for factor 
I mediated inactivation of C3b to iC3b. In addition, CFH competes with factor B for 
binding on surface bound C3b and accelerates the dissociation of C3-convertase. 
 
CFH is a single-chained (~155 kDa) glycoprotein consisting of 20 short consensus repeat 
(SCR) domains. (Figure 3) The first four domains of CFH serve as a cofactor and decay 
acceleration centers. The main surface recognition activities are associated with 
domains 19-20. CFH is known to interact with C3b by both domains 1-4 and 19-20. The 
principle of self vs non-self differentiation is based on interaction of CFH with C3b via 
domains 19-20 and its interaction with surface-bound glycosaminoglycans or sialic acids, 
which are not usually present on pathogen surfaces. CFH also reacts with heparin via 
domains 7 and 20 [1; 27.] 
 
Mutations or polymorphisms in CFH are known to be related to kidney diseases 
characterized by kidney malfunction due to uncontrolled complement activation. 
Mutations in domains 19-20 lead to aHUS, while mutations in amino-terminal domains 
may lead to dense deposit disease (DDD). Also, many CFH polymorphisms have been 
described: most CFH polymorphisms are connected to aHUS, but one polymorphism in 
domain 7, Y402H, is associated with age-related macular degeneration (AMD), the main 
cause of visual loss of the elderly in industrialized countries. This polymorphism has been 
shown to affect ability of factor H to bind to heparin and C-reactive protein (CRP), from 
which CRP is a biomarker of inflammation. The Y402 polymorphism also affects binding 
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of CFH to necrotic cells, leading to the increase or reduction of complement activation 
[1; 2.] 
 
Figure 3: CFH structure. Domains 1-4 serve as a cofactor and decay acceleration centers. 
Domains 19-20 are associated with surface recognition. Both domains 1-4 and 19-20 
are associated with CFH-C3b interaction. Domains 7 and 20 are associated with 
heparin binding. 
 
In addition to self-structures several microbes are known to bind CFH to allow 
complement regulation on their surfaces. This is one of the mechanisms of selective 
microbial alternative pathway evasion mechanisms. Most microbes bind CFH via two 
regions of this protein, domains 5-7 and 18-20 [1; 28.] 
 
 Apolipoprotein E (apoE)  
 
Apolipoprotein E (apoE) is a 34 kDa glycoprotein, associated with normal and altered 
lipid metabolism, where it transports lipids, vitamins as well as cholesterol into the lymph 
system and then into blood from hepatic cells (hepatocytes), which are the basic 
metabolic cells in liver. ApoE is an important protein for anti-microbial defense, oxidative 
stress and inflammation. ApoE can also be produced in the brain astrocyte cells and is 
the best expressed apolipoprotein in the cerebrospinal fluid [3.] 
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Structurally, apoE molecule consists of N-terminal domain (amino acids 1-191) and C-
terminal domain (~206-299), joined by a protease-sensitive loop. (Figure 4) The N-
terminal domain is a bundle of four helixes containing receptor-binding region and the 
heparan sulfate proteoglycan (HSPG) binding region. The C-terminal domain consists of 
amphipathic α-helix regions showing high affinity for lipid binding and apoE self-
associating region [3.] 
 
 
Figure 4: Apolipoprotein E structure. The N-terminal include the receptor binding region (green 
helix), which includes HSPG binding region and three other helixes (deep blue and light blue), 
one of which is not illustrated. The C-terminal domain include lipid-binding domain (yellow) and 
apoE self-association region (red) [29.] 
 
ApoE occurs in humans in three structurally and pathologically different isoforms: apoE2, 
apoE3 and apoE4. Because of their structural differences, three apoE isoforms have 
shown different binding to lipoproteins. ApoE2 is a genetic variant of apoE, associated 
with a condition called type III hyperlipoproteinemia (HLP), associated with increased 
cholesterol and decreased high-density lipoprotein (HDL) levels. ApoE3 is contributing 
to protection against cardiovascular disease (CVD). ApoE4 isoform is the risk factor in 
the development of Alzheimer’s disease (AD), the neurodegenerative disorder that 
ultimately leads to dementia. ApoE4 isoform is also connected to hepatitis C virus (HCV) 
and human immunodeficiency virus (HIV) [3.] 
 
Majority of apoE in plasma is produced by the liver and the molecule is mainly associated 
in very low-density lipoprotein (VLDL) or intermediate density lipoprotein (IDL) particles. 
Approximately 5-10% of apoE is, however, produced by macrophages. The endogenous 
production of apoE by macrophages in blood vessel walls has been shown to be critical 
in prevention and healing of atherosclerotic plaques. Atherosclerosis is a disease 
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characterized by chronic inflammatory response in the walls of arterial blood vessels 
where the complement system plays an important role. It has been previously shown 
that CFH domains 5-7 bind apoE and thereby reduces complement activation in plasma. 
[2] Interestingly, the common polymorphisms Y402H in CFH domain 7 that is associated 
with age-related macular degeneration (AMD) a disease that is significantly associated 
with occurrence of atherosclerosis [3.] 
 Aims of the Study 
 
The goal of this work was to express up to 10 mg of proteins CFH 5-7 and isolate apoE 
for X-ray crystallography and for biochemical assays aiming to study the role of apoE - 
CFH interaction in atherosclerosis. The main goal of CFH 5-7 expression was divided 
into two tasks: obtain new CFH expressing Pichia pastoris clone, and check CFH 5-7 
expression parameters using already made Pichia clone and try to express necessary 
amount of CFH 5-7. Theory and workflow of the methods used to achieve work objectives 
are explained in paragraphs 4 and 5. 
 
 Cloning, Expression and Purification of Complement Factor H 
 
There are many different protein expression systems, which are designed to produce 
multiple copies of required protein in a host cell and Pichia pastoris (Invitrogen) is one of 
such systems. Pichia pastoris has many of the advantages of eukaryotic expression 
systems. It is faster, easier to use, less expensive and more efficient comparing to other 
eukaryotic expression systems, such as mammalian cell culture. Pichia pastoris can be 
used to express proteins inside the cell (intracellular expression) or in the supernatant 
(extracellular expression). The main advantage of expressing proteins as secreted 
proteins during extracellular expression is that Pichia pastoris secretes very little 
amounts of non-target proteins, leading to the increase of target proteins in the 
expression medium [4.] 
 
 General Characteristics of Pichia pastoris  
 
Pichia pastoris is a methylotrophic yeast, capable of using methanol as its only carbon 
source. The process of methanol metabolism includes oxidation of methanol to 
formaldehyde, using molecular oxygen by the enzyme called alcohol oxidase, generating 
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hydrogen peroxide in the process. This process taxes place within peroxisome, a 
specialized cell organelle which separates toxic hydrogen peroxide by-products away 
from the rest of the cell. It is necessary for Pichia pastoris to generate large amounts of 
the alcohol oxidase, because this enzyme does not tolerate molecular oxygen well [5.] 
 
For this work a wild-type Pichia X-33 strain was used. This strain is useful for selection 
on Zeocin and large-scale growth. It uses yeast extract peptone dextrose (YPD) liquid 
media or agar plate for growth at 30 °C. Growth in temperatures above 30 °C significantly 
hinders protein expression or might even lead to cell death. It is advisable to add 0.5 – 1 
% of methanol to the media every day to induce protein expression in Pichia, when using 
plates or medium containing methanol, to compensate for loss because of evaporation 
or consumption [5.] 
 
 Vector selection  
 
Selection of the vector appropriate for protein expression is the first step in protein 
expression in Pichia. There are two expression vectors available to promote the 
expression of protein of interest in Pichia pastoris: pPICZ vector, which is used for 
intracellular protein expression and pPICZα, used for secreted expression (Invitrogen). 
These vectors provide high-level expression of the gene of interest in Pichia regulated 
by methanol induction. Each vector contains the Zeocin resistance gene, which allows 
vector-containing E. coli and Pichia organisms to grow in the presence of antibiotic 
Zeocin providing positive selection of these organisms [5.] 
 
pPICZα is a terminal fusion vector (Figure 5), available in three reading frames: pPICZα 
A, pPICZαB and pPICZα C. The vector used in this work, pPICZα B (3  7 bp), was 
previously tested for CFH expression in Pichia pastoris.  
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Figure 5: Contents of pPICZα vector. The vector contains AOX 1 promoter region, α-factor 
secretion signal, multiple cloning site with 12 unique restriction sites including Pst I 
restriction site, which was used for this work; C-terminal myc epitope tag, C- terminal 
polyhistidine (6*His) tag, AOX1 transcription termination (TT) region, TEF1 promoter 
region, EM7 promotion region, Zeocin resistant (Sh ble) gene, CYC1 transcription 
termination (TT) region and pUC origin region [4.] 
 
 Obtaining E. coli strain containing vector with gene of interest 
 
After choosing an appropriate vector, next step is to obtain E. coli clone that contain 
vector with the gene expressing protein of interest. The gene coding for the protein of 
interest needs to be ligated into vector. The vector then is transformed into E. coli strain 
and the successful transformation is confirmed by growing developed E. coli onto Low 
Salt LB plate in the presence of Zeocin. That allows positive selection of E. coli clones 
containing the insert, due to the presence of Zeocin resistant gene in the vector [5.] 
 
E. coli strain that was used in this work is called TOP10 (TOP10 Competent Cells, 
Thermo Fisher Scientific). TOP10 E. coli strain have a high transformation efficiency and 
they are recombination deficient (recA) and endonuclease A deficient (endA). E. coli 
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containing vector is grown in Luria-Bertani (LB) medium with lower than usual amount of 
salt, 0.5% instead of 1%. Use of higher than required salt concentration will inactivate 
the expression vector. The E. coli clone containing CFH 5-7 expression vector was 
obtained by Dr. Karita Haapasalo-Tuomainen prior to the beginning of this work [5.] 
 
 Plasmid transformation into Pichia Pastoris 
 
Obtained Zeocin-resistant (ZeoR) E. coli colonies all contained the expression vector with 
the inserted gene necessary for the plasmid transformation into Pichia. 
 
 Plasmid DNA extraction and purification 
 
It is required to extract E. coli plasmid DNA containing the insert and linearize it prior to 
transformation into Pichia using electroporation. If isolated plasmid DNA contains 
contaminants it is required to purify them using commercial kit. The GeneJET PCR 
purification system is commonly used to purify DNA from PCR reaction mixture but can 
also be used for different enzymatic reaction mixtures. After the purification, it is required 
to check plasmid DNA for complete purification using AGE. The desired amount of 
plasmid DNA for continuation of the work is 5 – 10 µg [4.] 
 
 Plasmid DNA digestion  
 
Prior to transformation into Pichia, E. coli plasmid DNA needs to be linearized for 
successful electroporation. Plasmid DNA can be linearized using DNA restriction 
enzyme Pme I that cut the expression vector at  ’ AOX  promoter region, resulting in 
linearized DNA molecule [4.] 
 
 Electroporation 
 
Electroporation is a method of DNA transfection into cells that utilizes high-voltage 
electric shock to the cell, resulting in the permeability increase of the cell membrane 
allowing DNA molecules to be introduced into the cell. Electroporation is the preferred 
method for transformation of Pichia pastoris with pPICZα because it does not destroy 
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the cell wall of Pichia. Usually, it provides 1000 – 10000 transformants per µg of digested 
plasmid DNA [6.] 
 
 Positive selection and cultivation of Pichia with CFH 5-7 colonies 
 
After incubation, electroporated cells are spread on YPDS agar plates, YPD agar plates 
containing sorbitol, with different added Zeocin concentrations and are then incubated at 
+ 30 °C for 3 – 10 days. Grown colonies are transferred onto a new YPDS plate, 
containing Zeocin, allowing for certain positive selection of Zeocin resistant clones. 
Obtained Pichia growth contain the inserted vector due to acquired resistance to Zeocin. 
The preference is given to the CFH 5-7 expressing Pichia clone grown in the highest 
Zeocin concentration plate [4.] 
 
 CFH 5-7 expression 
 
After obtaining the CFH 5-7 expressing Pichia clone, it is possible to start expression of 
the CFH 5-7. For protein expression in recombinant Pichia strains buffered complex 
glycerol (BMGY) medium and buffered minimal methanol (BMM) medium are needed. 
BMM and BMGY are buffers used for secreted protein expression, but BMGY is the 
medium used for Pichia growth prior to the expression, while BMM is used for the 
expression itself. BMGY medium differs from BMM because it contains yeast extract and 
peptone for stabilization of secreted proteins and prevention of proteolysis of secreted 
proteins.  
 
It is important, that during the expression the culture volume does not exceed 30 % of 
total flask volume to allow for adequate aeration during methanol induced protein 
expression [4.] 
 
 Purification of CFH 5-7 protein using affinity chromatography 
 
Affinity chromatography is a powerful tool for the purification of the specific proteins. The 
basic principle is that specific ligand is immobilized to a solid support of a column matrix. 
A solution containing the protein of interest is passed through the column and the protein 
in question reacts with the ligand, while other proteins are washed through the column.  
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The ability of CFH to bind to heparin by its 5-7 domains allows for selective binding of 
expressed CFH 5-7 in the Heparin column. Heparin is a member of a glycosaminoglycan 
family (5 – 30 kDa) of carbohydrates, consisting of repeated, differently sulfated 
disaccharide units. Heparin column is filled with cross-linked agarose beads, which are 
covalently bound to heparin, giving high capacity and performance for protein coupling. 
The binding process is stable in the pH range 5 – 10 and at the maximum speed of 1 
ml/min. Filtered supernatant is run through HiTrap Heparin column, which can be 
operated using either peristaltic pump or chromatography system. It is possible to isolate 
up to 3 mg of CFH 5-7 in one Heparin column [7.] The schematic representation of CFH 
5-7 isolation system used in this work is presented below. (Figure 5) 
 
 
Figure 5: Heparin column isolation system. The expression supernatant is run through the Heparin 
column using the peristaltic pump. 
 
 Salt gradient elution 
 
Recovery of the column-bound protein is achieved by changing salt concentration of the 
column solution. This is achieved by first purifying the column with filtered Aqua Milli-Q 
water, filtered 20 % ethanol solution and 75 mM PBS at the flow of 1 ml/min. Then the 
CFH 5-7 can be eluded by running 2 M NaCl/75mM PBS with the elution detection at 
280 nm. Salt molecules compete for binding to heparin with the CFH 5-7, resulting in 
elution of CFH 5-7 from the column in fractions.  
 
CFH 5-7 containing fractions must be checked for sample purity. The CFH 5-7 purity 
check is achieved by separating eluded charged molecules in the elution solution by their 
peristaltic pump
waste
expression
supernatant
 iTrap  eparin
column
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molecular masses using 10 % SDS-PAGE and staining them using Coomassie Instant 
Blue.  
 Dialysis and protein concentration measurement 
 
CFH 5-7 fractions need to be dialyzed to remove any unwanted molecules from the 
elution solution. Dialysis is used in the removal of salt molecules and small contamination 
proteins. The process of dialysis is based on random movement of the molecules that 
leads to the movement of molecules from high-concentration to low-concentration areas. 
Mixture, containing protein molecules is then transferred into semi-permeable 
membrane, allowing for diffusion of molecules with small molecular weight through 
membrane pores but restricting diffusion of big protein molecules into high amount of 
dialysis buffer, PBS. Slide-A-Lyser Dialysis Cassette is a dialysis system that was used 
for this work. It is composed of low-binding cellulose and is a hermetically sealed sample 
dialysis chamber allowing for efficient CFH 5-7 dialysis. 
 
After dialysis, concentration of CFH 5-7 in the sample is measured using Qubit 
Fluorometer (Life Sciences). Qubit Protein Assay is an easy, fast and accurate way to 
measure protein concentration. Qubit provides an accurate protein concentration 
measurement from 12,5 µg/ml to 5 mg/ml. It is required to prepare three (0, 200 and 400 
µg/ml) standards before preparing an aliquot of the isolated CFH 5-7 sample for 
concentration measurement [8.] Expressed CFH 5-7 can then be stored at –20 °C until 
further use. 
 Isolation of apoE  
 
ApoE is a lipid-binding protein resulting in formation of lipoproteins, so the quantitative 
isolation of apoE from human blood requires large amount of lipids. Hypertriglyceridemia 
is a condition that results in elevating numbers of fatty molecules, triglycerides, in human 
blood, so isolation of apoE from hypertriglyceridemia type IV or type V patients plasma 
is the most productive. It is required to dialyze samples before continuing with isolation. 
Isolation of apoE from human plasma occurs in several stages: lyophilization, 
delipidation, solubilization and size-exclusion chromatography [9; 10.] 
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 Lyophilization 
 
Dialyzed IDL-VLDL samples are very diluted, so the excess water needs to be removed 
from the samples. Lyophilization, or freeze-drying, is the process that allows water to 
sublime from the solid phase directly to the gas phase. It is achieved by freezing samples 
in dry ice to the lowest point possible, usually -80 oC quickly to avoid formation of ice 
crystals. Frozen samples are then put in freeze-dryer, Heto FD 2.5 to lower the sample 
pressure, resulting in sublimation of water from the sample and concentration of 
apolipoproteins in the sample, including apoE. 
 
 Delipidation 
 
Water-free IDL-VLDL samples need to be removed of lipids, resulting in the isolation of 
lipid-binding apolipoproteins in the supernatant. Delipidated samples are washed several 
times with methanol using low-speed centrifugation (1000 x g) before proceeding with 
solubilization, resulting in the formation of apolipoprotein pellet at the bottom of the flask. 
It is important to not allow the apolipoprotein pellet to dry and to proceed with 
solubilization of the apolipoproteins quickly. 
 
 Solubilization 
 
Pelleted apolipoproteins need to be prepared for gel filtration chromatography by 
reducing protein disulphide bridges and solubilized. Since apolipoproteins do not 
dissolve in normal conditions, homogeneous molecular dispersion of apolipoproteins in 
the solution is achieved by dissolving them in several substances that increase solubility 
of apolipoproteins [12.] 
 
 Gel filtration chromatography 
 
ApoE can be separated from other apolipoproteins in the solubilized apolipoprotein 
solution by  gel filtration through a gel consisting of spherical ~30 mm beads containing 
pores and allowing for specific size distribution thus separating apolipoproteins 
according to their size using gel filtration chromatography [13]. Characteristics and major 
functions of apolipoproteins are presented below. (Figure 6)  
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Figure 6: Apolipoproteins. In the sample may be present: apoA-V, apoC-I, apoC-II, apoC-III, 
apoB-100, apoE. [30] 
 
 Dot blot 
 
Isolated fractions can be checked for successful apoE isolation using dot blot procedure 
with anti-apoE antibody. Dot blot is a simplified version of the Western blot technique. 
To analyze the successful apoE isolation from the mix using dot blot technique, a small 
aliquot of the separated fractions is applied to the nitrocellulose membrane as a dot and 
then spotted using staining of the membrane with anti-apoE antibody. 
 
After isolation, it is possible to check apoE isolation purity using 10 % SDS-PAGE and 
stain with the Coomassie Instant Blue. If apoE sample contains contaminants it is 
possible to use specific binding of apoE to heparin to isolate apoE using HiTrap Heparin 
column and salt gradient elution as in CFH isolation. 
 Materials and Methods 
 
 Plasmid transformation 
 
The sample used for plasmid transformation was ready-made CFH 5-7 T54.6 402Tis 
PicZαB TOP10 E. coli clone.  
 
The sample was grown in 50 ml Low Salt LB medium at +37 oC over-night in the presence 
of Zeocin (Invitrogen) and plasmid DNA was isolated using GenElute HP Plasmid 
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Miniprep Kit’s protocol (Sigma Aldrich) or QIAprep Spin Miniprep Kit protocol (Qiagen). 
Isolated plasmid DNA was then checked for purity using 1% agarose gel electrophoresis 
(AGE). The presence of the plasmid DNA in the agarose gel was confirmed by screening 
the gel using GelDoc Molecular Imager (BIO-RAD).  
 
The GeneJET PCR purification kit (Thermo Fisher scientific) was used for plasmid DNA 
purification after isolation. The concentration of the isolated plasmid DNA was 
established using Nanodrop ND-1000, Thermo Fisher Scientific.  
 
Obtained amount of plasmid DNA was digested.  To perform DNA digestion, it was first 
required to prepare restriction mix: (Table 1) 
 
Table 1: Plasmid DNA digestion. During the first plasmid DNA linearization attempt the excessive 
amount of the Pme I restriction enzyme was used (30 U) 
 
Reagent Amount 
E. coli plasmid DNA/water 60 µl (5 – 10 µg) 
10x NEB buffer (Biolabs) 7 µl  
Pme I restriction enzyme (Thermo Fisher Scientific)  3 µl (20 U) 
Total volume 70 µl 
 
The plasmid DNA linearization was then performed by incubating the digestion mix at 
+37 oC for 1 h and then heat inactivating it by incubation at +65 oC for 20 minutes. 
Linearized plasmid DNA was then purified from the mix components using JeneJET 
purification kit protocol (Fermentas). The success of the linearization was confirmed by 
running 1 % AGE with 1 kb DNA ladder (GeneRuler).  
 
Before starting  the electroporation procedure, 500 ml of Pichia pastoris was grown in 
YPD medium for 2 days to a final overall density of the culture OD600= 1.3 – 1.5. Grown 
Pichia cells were then concentrated by centrifuging and resuspending cells in decreasing 
amount of ice-cold water and ice-cold 1 M sorbitol to a final volume of ~1,5 ml.  
 
80 µl of the concentrated Pichia cells were then mixed with linearized plasmid DNA and 
transferred to 0.2 cm electroporation cuvette (BIO-RAD). After 5 minutes incubation 
period the electroporation mix was pulsed at the resistance of     Ω, the capacitance of 
25 µF and the voltage of 1,5 kV, using Bio-rad Gene Pulser. Immediately after the 
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electroporation, 1 ml of ice-cold 1 M sorbitol was added, and the mixture was incubated 
for +30 °C for 1 - 2 hours.  
 
After incubation, the 10, 100 and 200 µl of electroporated cells are spread on YPDS agar 
plates with added 100, 500 and 2000 µg/ml Zeocin and incubated at +30 °C for 5 days.  
 
 CFH 5-7 expression 
 
The expression was performed from ready-made X-33 Pichia Pastoris clone containing 
CFH 5-7 expressing vector. Obtained Pichia sample was grown on YPDS plate at +30 
oC overnight. Grown Pichia colonies containing the insert were used for the CFH 5-7 
expression.  
 
The amount of protein-expressing Pichia Pastoris was increased by inoculating certain 
Pichia colony in 5 ml BMGY medium, containing 100 µg/ml Zeocin (Invitrogen), growing 
over-night at +30 °C and then repeating growth in 100 ml and 400 ml (for expression 
parameters check) or 1000 ml (for scale-up expression) of BMGY medium. Grown cells 
were harvested by centrifugation, using Avanti J-26 centrifuge (Beckman Coulter) at 
1,500 – 3,000 x g for 5 minutes at room temperature and the cell pellet was resuspended 
in BMM medium to OD600 = 1.0 – 1.2 to induce expression. 
 
Expression mix was then grown in Innova 4330 refrigerated shaking incubator (New 
Brunswick Scientific) at 29,5 °C, 250 rpm for 5 days with daily methanol inductions up to 
1,0 % of the total expression mix.  
 
After expressing Pichia with insert for appropriate amount of time, the expression 
supernatant was collected by centrifuging expression cell mix 3 times at 1.500 - 3,000 x 
g for 15 minutes at room temperature using Avanti J-26 centrifuge and disposing of the 
cell pellet. The pH of the expression supernatant was adjusted to 6.5 using 0.2 M 
Na2HPO4. During scale-up CFH 5-7 expression it was decided to check pH of the 
expression mix daily before methanol induction and keep pH at 6.0 with 1 M K2HPO4, 
because of the susceptibility of the expression inducing enzymes, proteases, to the low 
pH that might lead to a complete inactivation of the process. The expression supernatant 
was filtered using 0.8 and 0.2 µm vacuum filters (Thermo Scientific). 
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Purification of CFH 5-7 protein was performed by running the expression supernatant 
through the HiTrap Heparin column (Healthcare) at the speed of 0.5 ml/min over-night 
for expression parameter check and 1.0 ml/min during the scale-up expression. 
 
After CFH 5-7 isolation in the Heparin column, CFH 5-7 was separated from the Heparin 
column using Äkta salt-gradient elution purifier. CFH 5-7 was eluded by washing the 
Heparin column with the 2M NaCl/75mM PBS. The fractions containing the CFH 5-7 
were checked for purity by running them in 10 % SDS-PAGE gel. The gel was stained 
with the Coomasie Instant Blue (Invitrogen). 
 
The collected CFH 5-7 expression fractions were then pooled together into two samples 
(High and Low concentration) and dialyzed using Slide-A-Lyser Dialysis Cassettes. 
Dialysis was performed by loading CFH 5-7 containing samples into Slide-A-Lyser 
Dialysis Cassettes (Thermo Scientific) and placing the cassettes in 4l of PBS overnight 
at +4 °C.  
 
The concentration of dialysed CFH 5-7 samples was measured using Qubit Fluorometer 
and the total amount of the protein present in the sample was calculated based on the 
concentration provided. 
 
 ApoE isolation 
 
The process of apoE isolation from isolated intermediate-density lipoproteins (IDL) and 
very low-density lipoproteins (VLDL) plasma samples was performed from H296 and 
H333 plasma samples, obtained from Dr. docent Matti Jauhiainen. The IDL and VLDL 
were isolated in H296 and H333 samples by sequential ultracentrifugation (UCF) at 
density 1.006 – 1.019 g/ml prior to the beginning of this work.  
 
Obtained IDL-VLDL samples were filtered to remove clumps and dialyzed using 
regenerative cellulose (RC) Dialysis Membrane at density <1.019 g/ml in 0.01% EDTA 
at pH 7.4. 
 
Dialyzed IDL-VLDL samples were then lyophilized by freezing dialyzed samples in dry-
ice with ethanol for ~30 minutes, while inverting the tube to let ice crystals form on the 
side. Frozen IDL-VLDL samples were transferred to the Heto FD 2.5 lyophilizer and the 
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pressure was lowered to less than 10 mbar, resulting in the sublimation of water from 
the samples. 
 
Water-free IDL-VLDL samples were then delipidated by adding ~30 ml of chloroform – 
methanol, 2:1, v/v to the ~50 mg of the sample and incubated for 1h at +4 oC. 
Resuspended 3 times in 20 ml methanol by centrifuging at 1000 x g and resuspending 
to pellet apolipoproteins. 
 
Pelleted apolipoproteins were then solubilized by resuspending the pellet in ultrapure 6 
M guanidine (minimal absorbance at 280 nm) (Sigma-Aldrich), 0.1 M Tris, 0.01% EDTA 
(pH 7.4) and 1% 2-mercaptoethanol over-night at room temperature. Any insoluble 
material was removed by low-speed centrifugation (300 x g for 10 min) and preserved 
for repeated solubilization. 
 
The solubilized apoE samples (~3 ml) were separated from other apolipoproteins and 
detected at A280 nm by running apoE samples through the PBS cleaned Hiload Superdex 
16/600 200 pg column (Healthcare), with the flow of 1 ml/min.  
 
To analyze the successful apoE isolation from the mix using dot blot technique, a small 
aliquot of the separated fractions is applied to the nitrocellulose membrane (Sigma-
Aldrich) as a dot, blocked for 2 h at room temperature using 5% milk/PBS and then 
spotted by staining the membrane with polyclonal anti-apoE Rabbit lgG  107 Bl XIII lgG 
antibody diluted 1:10,000 in 1 % milk/PBS overnight at +4 oC. Isolated fractions were 
detected with the secondary antibody IRDye 800CW Donkey anti-Rabbit lgG diluted 
1:10,000 on the anti-apoE stained membrane using Li-COR Odyssey Infrared Imaging 
System. 
 Results 
 
 Obtaining high CFH 5-7 expressing Pichia clone 
 
In total, two attempts to transform E. coli plasmid DNA into Pichia Pastoris were made. 
The goal of the first attempt was to check described E. coli plasmid DNA transformation 
parameters. Because of the insufficient growth time of the E. coli grown in 50 ml Low 
Salt LB medium, the total calculated mass of the isolated plasmid DNA was only 1.56 µg 
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(31.2 µg/ml). Even though according to the described procedure at least 5 µg of plasmid 
DNA was needed for successful transformation, it was decided to continue with 
electroporation using obtained amount of plasmid DNA. After 5 days incubation period, 
four electroporated Pichia colonies that grew on YPDS plates containing Zeocin were 
obtained. They were grown overnight on a new YPDS plates with 100 µg /ml Zeocin and 
checked for protein expression by growing them overnight in 50 ml of BMGY medium 
and resuspending in 100 ml of BMM medium. Expression supernatant was collected and 
analyzed using SDS-PAGE after 9 days of expression. All 4 Pichia clones did not show 
CFH expression and were discarded.  
 
Second attempt to obtain high FH 5-7 expressing Pichia clone was performed using the 
same plasmid DNA transformation procedure as the first attempt. After the first failure to 
produce sufficient amount of E. coli plasmid DNA the E. coli was grown in 50 ml of Low 
Salt LB medium for 2 days to obtain sufficient amount of E. coli growth. The total 
calculated mass of the isolated E. coli plasmid DNA was 83.8 µg (167.6 µg/ml). The 
aliquot of plasmid DNA containing calculated amount of 10.02 µg E. coli plasmid DNA 
was used for the electroporation. After 5 days incubation period, only one electroporated 
Pichia colony grew on YPDS plates containing Zeocin. It was stored at -20 oC to be 
checked for CFH 5-7 expression in the future by my supervisor. 
 
 CFH 5-7 expression  
 
In total, two successful attempts were performed in order to express CFH 5-7. The 
protein expression was performed, as described in 6.2. The primary goal of the first 
expression attempt was to check described expression parameters. For that purpose, 
the insert-containing Pichia clone was grown in the final volume of 400 ml BMGY medium 
and then expressed for 5 days in BMM medium with daily methanol additions. The 
successful isolation of the CFH 5-7 in the Heparin column was confirmed by eluding a 
small volume of CFH 5-7 from the Heparin column (~200 ml) by running 50 ml of 2 M 
NaCl/ PBS through and analyzing the eluded CFH 5-7 sample by running it in 10 % SDS-
PAGE gel and staining it using Coomassie Instant Blue. (Figure 7)  
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Figure 7: SDS-PAGE of the Heparin column sample, containing the Kaleidoscope Precision Plus 
Protein Standards (left) and eluded CFH 5-7 (right). The eluded samples clearly show 
the isolation of the CFH 5-7 size band (~19 kDa).  
 
The remaining amount of the CFH 5-7 isolated into the new Heparin column was 
separated from using Äkta salt-gradient elution purifier. (Figure 8) The fractions 
containing the CFH 5-7 were analyzed for purity using 10 % SDS-PAGE gel and stained 
using Coomassie Instant Blue. The fractions appeared to be contaminant-free. (Figure 
9) After the 10 % SDS-PAGE purity check the fractions containing the largest amount of 
CFH 5-7 (A7, A8, A9, A10) were pooled together, forming High Concentration sample 
and the rest (A6, A11, A12, A13) were pooled together to form Low Concentration 
sample. 
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Figure 8: CFH 5-7 salt gradient elution. Fractions A4 – A13 contained the expressed CFH 5-7.  
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Figure 9: Purity check of the CFH 5-7 protein expression solution isolated from Heparin column 
on 10% SDS-PAGE gel, containing the Kaleidoscope Precision Plus Protein Standards 
(right) and separated CFH 5-7 fractions (left).  
 
After the first successful CFH 5-7 isolation, it was decided to scale-up CFH 5-7 
expression. For that purpose, the Pichia clone was grown in 1l of BMGY medium and 
expressed for 5 days in BMM medium with daily methanol additions. It was also decided 
to keep the pH of the expression medium at 6.0 - 6.5 by adding 0.2 M Na2HPO4 to not 
allow inactivation of the expression vector.  
 
After performing salt gradient elution, the fractions containing the CFH 5-7 (Figure 10) 
were analysed for purity using SDS-PAGE. The fractions containing the largest amount 
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of CFH 5-7 (A7, A8, A9, A10) were pooled together, forming High Concentration sample 
and the rest (A6, A11) were pooled together to form Low Concentration sample. 
 
 
Figure 10: Second CFH 5-7 salt gradient elution. Fractions A6 – A11 contained the expressed 
CFH 5-7. 
 
The concentrations of the expressed High and Low Concentration CFH 5-7 samples 
measured using Qubit Fluorometer during the first expression attempt were 76.4 µg/ml 
and 130.0 µg/ml and the during the second expression attempt were 61.2 µg/ml and 138 
µg/ml. The total calculated amount of the expressed CFH 5-7 from total amount of 1.4 l  
Pichia growth was 398.86 µg. 
 
 ApoE isolation 
 
It was attempted to separate apoE from ~3 ml of solubilized IDL-VLDL H296 and H333 
samples using gel filtration chromatography by running IDL-VLDL sample supernatant 
through the Hiload Superdex 16/600 200 pg column and detect separated apoE at A280 
nm using Äkta purifier. (Figures 12, 13)  
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Figure 12: Gel filtration chromatography of H296. Based on the dot blot analysis it was established 
that apoE containing fractions are A1-D9. 
 
Figure 13: Gel filtration chromatography of H333. Based on the dot blot analysis it was established 
that apoE containing fractions are A4 – D2. 
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The separated apolipoprotein fractions were then analyzed using dot blot technique. 
(Figure 14) 
 
Figure 14: Dot blot of the isolated H296 (left) and H333 (right) fractions. Fractions containing apoE 
are highlighted. 
 
The dot blot was the last thing that was managed to do for the apoE isolation on the time 
of this project, but a small amount of apoE was isolated and checked for purity by running 
the samples in the 10 % SDS-PAGE gel by my supervisor. (Figure 15) 
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Figure 15: SDS-PAGE of the purified apoE (~34 kDa). H333 (left), H296 (middle) and 
Kaleidoscope Precision Plus Protein Standards (right). 
 Discussion 
 
The processes of CFH 5-7 expression and apoE isolation in this experimental work 
proved to be more challenging and time-consuming than initially anticipated. Several 
experimental attempts were made to obtain the desired result, which indicates the need 
for precision and vigilance when performing the procedures.  
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Two attempts to transform CFH expressing vector into Pichia pastoris were made. The 
first attempt was not successful, even though four Pichia strains were grown in the 
presence of Zeocin, they did not show production of CFH 5-7 when performing the 
expression.  During the second attempt one Pichia strain grew in the presence of Zeocin, 
but the remaining amount of time for this work was not sufficient to check it for CFH 5-7 
expression. My laboratory work time was already at an end, so it was not possible to 
check obtained Pichia clone for CFH 5-7 expression. 
 
In total, three attempts to express CFH 5-7 from ready-made Pichia pastoris clone were 
performed. First two expression attempts were successful. The quality of the expressed 
CFH 5-7 was enough for the planned biochemical experiments, but larger amounts of 
protein were required for X-ray crystallography. The third expression attempt failed due 
to the contamination of the expression mix: at the end of the five days expression it was 
not possible to purify the supernatant of CFH 5-7 expression because of the apparent 
BMGY or BMM medium contamination. The third protein expression sample was 
discarded.   
 
During this experimental work the expression and purification of high quality CFH 5-7 
was successfully performed, which indicates that processes of CFH 5-7 expression and 
isolation from Pichia work fine. The expressed high-quality CFH 5-7 fragments are the 
absolute requirements for the future assays. Although, the amount of expressed CFH 5-
7 was not enough for x-ray crystallography, the purity of the expressed protein met 
required standards. In addition to producing these proteins for the laboratory use I re-
wrote the experiments and recipes for the required buffers and media. These will be in 
great need for the new students and researchers performing the same experiments. 
 
The success of CFH 5-7 expression was at least encouraging to my supervisor. It was 
decided to use the expressed CFH 5-7 for another laboratory work that requires high-
quality CFH 5-7 without any contaminants. The plan for continuation of this work was to 
obtain a high CFH 5-7 expressing Pichia clone with the same purity levels. The process 
of plasmid DNA transformation into Pichia will also require some optimization in the 
future. 
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BMGY medium recipe 
 
Definition: 
• Prepare 1 M Potassium Phosphate buffer (pH 6.0): 
Combine 132 ml of 1 M K2HPO4 and 868 ml of 1 M KH2PO4, confirm that pH = 6.0±0.1 
(if pH needs to be adjusted, use phosphoric acid or KOH). Sterilize by autoclaving 
and store at RT. 
• Prepare solutions 1 and 2 
Recipe: solution 1                                                                                                      Amount / 1l 
 
Bact. Yeast extract                                                                                                        10 g 
Bact. Peptone 20 g 
Biotin     2 ml/l = 0.4 mg 
Glyserol 10 ml 
1 M Potassium Phosphate buffer (pH 6.0) (keep in RT) 100 ml 
Aq. dest.         adjust to  900 ml 
Sterilization: Autoclave 15 min at +121 oC. 
 
Recipe: solution 2            Amount / 1l 
 
YNB = yeast nitrogen base*  13.4 g 
Aq. steril.                                                                                                                         100 ml 
Make sure YNB contains ammonium sulfate 
Filtrate solution 2 with Millipore (filter size – 0.22 µm) 
• Combine solutions 1 and 2 
Storage: fridge at +4 oC 
Biotin dilution: dissolve 20 mg of Biotin / 100 ml of sterilized water and sterile filtrate (filter size 
– 0.22 µm). Store in fridge. 
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BMM medium recipe 
Definition:  
• Prepare 1 M Potassium Phosphate buffer (pH 6.0): 
Combine 132 ml of 1 M K2HPO4 and 868 ml of 1 M KH2PO4, confirm that pH = 6.0±0.1 
(if pH needs to be adjusted, use phosphoric acid or KOH). Sterilize by autoclaving 
and store at RT 
• Prepare solutions 1 and 2 
Recipe: solution 1                                                                                         Amount / 1l 
 
Biotin      2 ml/l = 0.4 mg 
Methanol 5 ml 
1 M Potassium Phosphate buffer (pH 6.0) (keep in RT) 100 ml 
Aq. dest.          adjust to 900 ml 
Sterilization: Autoclave 15 min at +121 oC 
 
Recipe: solution 2            Amount / 1l 
 
YNB = yeast nitrogen base* 13.4 g 
Aq. steril.                                                                                                                       100 ml 
Make sure YNB contains ammonium sulfate 
Filtration with Millipore (filter size – 0.22 µm) 
• Combine solutions 1 and 2 
Storage: fridge +4 oC 
Biotin dilution: dissolve 20 mg of Biotin / 100 ml of sterilized water and sterile 
filtrate (filter size – 0.22 µm). Store in fridge. 
 
1 M Sorbitol recipe 
• For 1l: dissolve 18,21 g of D-sorbitol in 100 ml of water 
• Adjust to 1l with water 
• Filter, using vacuum filters 
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YPDS agar plate recipe (+ Zeocin) 
• For 1l: dissolve the following in 900 ml of water: 
10 g yeast extract 
182.2 g sorbitol 
20 g peptone 
• Add 20 g agar 
• Autoclave for 20 min on liquid cycle 
• Add 100 ml of 20 % Dextrose 
• Cool solution to 60 oC (and add 1.0 ml of 100 mg/ml Zeocin, if needed) 
• Store YPDS plates at 4 oC, in the dark (1-2 weeks) 
 
YPD medium recipe (+ Zeocin) 
• For 1l: dissolve in 900 ml water: 
10 g yeast extract 
20 g peptone 
• Autoclave for 20 min on liquid cycle 
• Add 100 ml of 20 % Dextrose 
• Cool solution to 60 oC (and add 1.0 ml of 100 mg/ml Zeocin, if needed) 
• Store YPDS plates at 4 oC, in the dark (1-2 weeks) 
 
 
0.2 M Na2HPO4 recipe  
• For 1l: dissolve 28,39 g of Na2HPO4 in 100 ml of water 
• Adjust to 1l with water 
• Filter, using vacuum filters 
 
1 M K2HPO4 recipe  
• For 1l: dissolve 228,23 g of K2HPO4*3H2O in water 
• Adjust to 1l with water 
• Filter, using vacuum filters 
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E. coli Low Salt LB medium recipe 
• For 1 liter, dissolve the following in 950 ml deionized water: 
10 g tryptone 
5 g Yeast Extract 
0.5 % NaCl 
• Adjust pH of the solution to 7.5 with 1N NaOH and bring the volume up to 1 liter 
• Autoclave for 20 minutes at 15 lb/sq. in and 121 oC 
• Let cool to 55 oC (and add Zeocin to 25 µg/ml final concentration, if needed) 
• Store at 4 oC in the dark (1-2 weeks) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 2 
1 (1) 
 
 
AGE: 
 
Prepare 1 l electrophoresis buffer (1x TBE) to fill the electrophoresis tank and to 
cast the gel: 
For this we take 100 ml of 10x TBE (89 mM Tris, 89 mM boric acid, 2 mM EDTA) stock 
solution in an Erlenmeyer flask and make the volume to 1000 ml by adding 900 ml of 
distilled water. The 1x working solution is 8.9 mM Tris-borate-EDTA (TBE) 
It is important to use the same batch of electrophoresis buffer in both the 
electrophoresis tank and the gel preparation. 
  
Prepare a solution of agarose in electrophoresis buffer at an appropriate 
concentration: 
For this weight 1.5 grams of agarose to 150 ml of electrophoresis buffer. 
 
Loosely plug the neck of the Erlenmeyer flask. Heat the slurry in a microwave oven until 
the agarose dissolves. The agarose solution can boil over very easily so keep checking 
it. It is good to stop it after 45 seconds and give it a swirl. It can become superheated 
and NOT boil until you take it out whereupon it boils out all over your hands. Wear gloves 
and hold it at arm's length. Use insulated gloves or tongs to transfer the flask/bottle into 
a water bath at 55°C. When the melted gel has slightly cooled, add 6 µl of 0.04 µg/ml 
Midori Green (Nippon Genetics), fluorescent dye used for staining nucleic acids. Mix the 
gel solution thoroughly by gentle swirling.  
   
While the agarose solution is cooling, choose an appropriate comb for forming the 
sample slots in the gel. 
  
Pour the warm agarose solution into the mold. 
(The gel should be between 3 - 5 mm thick. Check that no air bubbles are under or 
between the teeth of the comb.) 
  
Allow the gel to set completely (30-45 minutes at room temperature), then pour a small 
amount of electrophoresis buffer on the top of the gel, and carefully remove the comb. 
Pour off the electrophoresis buffer. Mount the gel in the electrophoresis tank. 
 
 
